TABLE 2.

Follow-up of 20 patients of the study^a

Patient no.	Pattern 69, baseline	Antiretroviral therapy	Time of follow-up (weeks)	Δ log10 HIV-1 RNA	Pattern 69, follow-up
3	S-D	AZT 3TC APV	8	0.25	ND
6	S-SG	ABC NVP NFV SQV	36	−0.82	S-ST/S
9	S-CA	d4T 3TC RTV SQV EFV	40	0.36	S-CA
10	S-VG	Megahaart	10	−2.26	ND
12	S-SG	2 months wash-out	35	−0.47	S
13	S-SG	3 months wash-out	13	−0.26	ND
15	S-TT	ddI EFV NFV SQV	64	−2.06	ND
16	S-SG	AZT 3TC EFV RTV SQV	8	0.11	ND
17	S-SA	d4T 3TC APV	24	0.22	ND
18	S-SS	d4T 3TC NFV	4	−1.01	ND
21	S-ES	ABC NFV NVP	16	0.48	ND
23	S-SG	AZT 3TC ABC NVP SQV	24	−0.32	ND
25	S-MT	d4T 3TC IDV	28	−3.19	ND
26	S-ST	d4T 3TC RTV	8	−2.03	ND
29	S-SS	d4T 3TC IDV	28	0.76	ND
30	S-SG	ABC SQV RTV	22	1.68	ND
31	S-SG	AZT 3TC RTV	36	−0.93	S-SG
47	Insertion 5 aa	ddI ABC EFV	24	0.12	ND
48	Insertion 11 aa	d4T ddI NVP NFV	24	−0.74	Insertion 11 aa
52	Deletion	d4T 3TC NFV	24	0.07	ND

^aΔ log₁₀ HIV-1 RNA, changes of the HIV plasma viral load from the baseline. Antiretroviral therapy, the drugs which were absent at baseline appear in bold (can be recycled from previous regimens). Megahaart, 8 antiretroviral drugs combined with hydroxyurea. Pattern 69, genotype at codon 69 and rearrangements. ND, genotype not determined. RTV, ritonavir; SQV, saquinavir; IDV, indinavir; NFV, nelfinavir.